Baltimore, Maryland 21205

  • Alcoholism


This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.


Inclusion Criteria: - Meets criteria for alcohol dependence. - Committed to alcohol abstinence as a treatment goal. - Individuals will be required to identify two family members or close friends who are knowledgeable about their location, drinking behavior, and psychosocial status. Exclusion Criteria: - Meets criteria for any other psychoactive substance use disorder (excluding nicotine and caffeine). - Meets criteria for a major psychiatric disorder and are in need of or currently undergoing pharmacotherapy. - Females who are pregnant, lactating, or not using a reliable method of contraception. - Currently experiencing a serious medical condition that would place them at risk or interfere with study participation. - Experiencing acute hepatitis or liver failure or whose liver function test is more than 3 times normal. - Have a history of severe allergies, multiple adverse drug reactions or known allergy to naltrexone. - Vocabulary below the 5th grade reading level. - Abnormal MRI scan. - HIV infection due to the neurological sequelae. - Significant central nervous system diseases. - Seizure disorder or history of closed head trauma. - Neuroendocrine disorders. - Treatment with opiates within the last six months.



Primary Contact:


Backup Contact:


Location Contact:

Baltimore, Maryland 21205
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.